Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports
Published in: Current Hypertension Reports 5/2010

01-10-2010

Prevalence and Diagnosis of Primary Aldosteronism

Author: Gian Paolo Rossi

Published in: Current Hypertension Reports | Issue 5/2010

Login to get access

Abstract

Primary aldosteronism (PA) is a common cause of arterial hypertension: in the PA Prevalence in Hypertensives (PAPY) Study, the prevalence of PA was 11.2% in consecutive referred hypertensive patients. When adrenal vein sampling (AVS) is available, two thirds of the cases can be attributed to a tumor and one third of cases are idiopathic; the opposite is seen when AVS is unavailable. Thus, AVS influences the relative prevalence rate of the main subtypes of PA. When adrenalectomy is undertaken based on AVS, almost 100% of patients are cured of hyperaldosteronism, one third are cured of hypertension, and 52% are markedly improved in terms of blood pressure control. Persistent hypertension can be predicted by a long history of hypertension and by the presence of excessive cardiovascular damage, including vascular remodeling. Therefore, an early diagnosis is crucial to achieve cure. This review discusses the implications of the high prevalence of PA for its diagnostic strategy.
Literature
1.
Conn JW: Presidential address. I. Painting background. II. Primary aldosteronism, a new clinical syndrome. J Lab Clin Med 1955, 45:3–17.PubMed
2.
Rossi GP: Surgically correctable hypertension caused by primary aldosteronism. Best Pract Res Clin Endocrinol Metab 2006, 20:385–400.CrossRefPubMed
3.
• Schupp N, Queisser N, Wolf M, et al.: Aldosterone causes DNA strand breaks and chromosomal damage in renal cells, which are prevented by mineralocorticoid receptor antagonists. Horm Metab Res 2010, 42:458–465. This study shows that aldosterone causes oxidative DNA damage, which could be prevented by MR antagonists.CrossRefPubMed
4.
Rocha R, Rudolph AE, Frierdich GE, et al.: Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol 2002, 283:H1802–H1810.PubMed
5.
Brilla CG, Maisch B, Weber KT: Myocardial collagen matrix remodelling in arterial hypertension. Eur Heart J 1992, 13(Suppl D):24–32.PubMed
6.
Rossi GP, Sacchetto A, Pavan E, et al.: Remodeling of the left ventricle in primary aldosteronism due to Conn’s adenoma. Circulation 1997, 95:1471–1478.PubMed
7.
Rossi GP, Di Bello V, Ganzaroli C, et al.: Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 2002, 40:23–27.CrossRefPubMed
8.
Farquharson CA, Struthers AD: Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 2002, 103:425–431.
9.
Rizzoni D, Muiesan ML, Porteri E, et al.: Relations between cardiac and vascular structure in patients with primary and secondary hypertension. J Am Coll Cardiol 1998, 32:985–992.CrossRefPubMed
10.
Rossi GP, Bernini G, Desideri G, et al.: Renal damage in primary aldosteronism: results of the PAPY study. Hypertension 2006, 48:232–238.CrossRefPubMed
11.
• Rossi GP, Sechi LA, Giacchetti G, et al.: Primary aldosteronism: cardiovascular, renal and metabolic implications. Trends Endocrinol Metab 2008, 19:88–90. This review article provides updated information on the involvement of excess aldosterone in causing target organ damage in hypertension and in worsening the prognosis of patients with heart failure and post-MI patients.CrossRefPubMed
12.
Sechi LA, Novello M, Lapenna R, et al.: Long-term renal outcomes in patients with primary aldosteronism. JAMA 2006, 295:2638–2645.CrossRefPubMed
13.
Milliez P, Girerd X, Plouin PF, et al.: Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005, 45:1243–1248.CrossRefPubMed
14.
• Rossi GP, Bolognesi M, Rizzoni D, et al.: Vascular remodeling and duration of hypertension predict outcome of adrenalectomy in primary aldosteronism patients. Hypertension 2008, 51:1366–1371. This paper provides solid information on the effect of adrenalectomy on hyperaldosteronism and blood pressure when the patients are selected for adrenalectomy based on demonstration of lateralized aldosterone excess. It also identifies the predictors of the blood pressure outcome.CrossRefPubMed
15.
• Catena C, Colussi G, Lapenna R, et al.: Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007, 50:911–918. This paper provides information on the effects of adrenalectomy and treatment with MR antagonists on left ventricular mass index.CrossRefPubMed
16.
Gordon RD, Ziesak MD, Tunny TJ, et al.: Evidence that primary aldosteronism may not be uncommon: 12% incidence among antihypertensive drug trial volunteers. Clin Exp Pharmacol Physiol 1993, 20:296–298.CrossRefPubMed
17.
Anderson GH, Jr., Blakeman N, Streeten DH: The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 1994, 12:609–615.CrossRefPubMed
18.
Gordon RD, Stowasser M, Tunny TJ, et al.: High incidence of primary aldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994, 21:315–318.CrossRefPubMed
19.
Rossi GP, Rossi E, Pavan E, et al. Screening for primary aldosteronism with a logistic multivariate discriminant analysis. Clin Endocrinol (Oxf) 1998, 49:713–723.CrossRef
20.
Rossi GP: Primary aldosteronism: a needle in a haystack or a yellow cab on Fifth Avenue? Curr Hypertens Rep 2004, 6:1–4.CrossRefPubMed
21.
Rossi GP, Pessina AC, Heagerty AM: Primary aldosteronism: an update on screening, diagnosis and treatment. J Hypertens 2008, 26:613–621.CrossRefPubMed
22.
• Rossi GP, Seccia TM, Pessina AC: Clinical use of laboratory tests for the identification of secondary forms of arterial hypertension. Crit Rev Clin Lab Sci 2007, 44:1–85. This review article provides updated information on laboratory tests, including the renin and aldosterone assay, for identifying the secondary forms of arterial hypertension.CrossRefPubMed
23.
Funder JW, Carey RM, Fardella C, et al.: Case detection, diagnosis, and treatment of patients with primary aldosteronism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2008, 93:3266–3281.CrossRefPubMed
24.
Rossi GP, Bernini G, Caliumi C, et al.: A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol 2006, 48:2293–2300.CrossRefPubMed
25.
Rossi GP, Belfiore A, Bernini G, et al.: Body mass index predicts plasma aldosterone concentrations in overweight-obese primary hypertensive patients. J Clin Endocrinol Metab 2008, 93:2566–2571.CrossRefPubMed
26.
Sealey JE, Gordon RD, Mantero F: Plasma renin and aldosterone measurements in low renin hypertensive states. Trends Endocrinol Metab 2005, 16:86–91.CrossRefPubMed
27.
Campbell DJ, Nussberger J, Stowasser M, et al.: Activity assays and immunoassays for plasma renin and prorenin: information provided and precautions necessary for accurate measurement. Clin Chem 2009, 55:867–877.CrossRefPubMed
28.
• Rossi GP, Barisa M, Belfiore A, et al.: The aldosterone renin ratio based on the plasma renin activity and the direct renin assay for diagnosing aldosterone-producing adenoma. J Hypertens 2010 (in press). This paper provides information on the performance of the direct renin assay as compared with the plasma renin assay for the identification of APA.
29.
Stowasser M, Gordon RD, Gunasekera TG, et al.: High rate of detection of primary aldosteronism, including surgically treatable forms, after “non-selective” screening of hypertensive patients. J Hypertens 2003, 21:2149–2157.CrossRefPubMed
30.
• Rossi GP, Seccia TM, Palumbo G, et al.: Within-patient reproducibility of the aldosterone:renin ratio in primary aldosteronism. Hypertension 2010, 55:83–89. This paper investigated the reproducibility of the ARR when repeated in the same patients under standardized conditions.CrossRefPubMed
31.
Irony I, Kater CE, Biglieri EG, Shackleton CH: Correctable subsets of primary aldosteronism. Primary adrenal hyperplasia and renin responsive adenoma. Am J Hypertens 1990, 3:576–582.PubMed
32.
Gordon RD, Gomez-Sanchez CE, Hamlet SM, et al.: Angiotensin-responsive aldosterone-producing adenoma masquerades as idiopathic hyperaldosteronism (IHA: adrenal hyperplasia) or low-renin hypertension. J Hypertens Suppl 1987, 5(Suppl 5):S103–S106.PubMed
33.
• Rossi GP, Belfiore A, Bernini G, et al.: Comparison of the captopril and the saline infusion test for excluding aldosterone-producing adenoma. Hypertension 2007, 50:424–431. This study compared head-to-head the captopril and the saline infusion tests for excluding APA under different sodium intakes.CrossRefPubMed
34.
Rossi GP, Chiesura-Corona M, Tregnaghi A, et al.: Imaging of aldosterone-secreting adenomas: a prospective comparison of computed tomography and magnetic resonance imaging in 27 patients with suspected primary aldosteronism. J Hum Hypertens 1993, 7:357–363.PubMed
35.
Rossi GP, Vendraminelli R, Cesari M, Pessina AC: A thoracic mass with hypertension and hypokalaemia [case report]. Lancet 2000, 356:1570.CrossRefPubMed
36.
Seccia TM, Fassina A, Nussdorfer GG, et al.: Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn’s syndrome with an ominous clinical course. Endocr Relat Cancer 2005, 12:149–159.CrossRefPubMed
37.
Omura M, Sasano H, Fujiwara T, et al.: Unique cases of unilateral hyperaldosteronemia due to multiple adrenocortical micronodules, which can only be detected by selective adrenal venous sampling. Metabolism 2002, 51:350–355.CrossRefPubMed
38.
Magill SB, Raff H, Shaker JL, et al.: Comparison of adrenal vein sampling and computed tomography in the differentiation of primary aldosteronism. J Clin Endocrinol Metab 2001, 86:1066–1071.CrossRefPubMed
39.
Mantero F, Terzolo M, Arnaldi G, et al.: A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab 2000, 85:637–644.CrossRefPubMed
40.
Young WF, Stanson AW, Thompson GB, et al.: Role for adrenal venous sampling in primary aldosteronism. Surgery 2004, 136:1227–1235.CrossRefPubMed
41.
• Kempers MJ, Lenders JW, van Outheusden L, et al.: Systematic review: diagnostic procedures to differentiate unilateral from bilateral adrenal abnormality in primary aldosteronism. Ann Intern Med 2009, 151:329–337. This study is a meta-analysis of different procedures used for differentiation of PA subtypes.PubMed
42.
Rossi GP: New concepts in adrenal vein sampling for aldosterone in the diagnosis of primary aldosteronism. Curr Hypertens Rep 2007, 9:90–97.CrossRefPubMed
43.
Rossi GP, Pitter G, Bernante P, et al.: Adrenal vein sampling for primary aldosteronism: the assessment of selectivity and lateralization of aldosterone excess baseline and after adrenocorticotropic hormone (ACTH) stimulation. J Hypertens 2008, 26:989–997.CrossRefPubMed
44.
Daunt N: Adrenal vein sampling: how to make it quick, easy, and successful. Radiographics 2005, 25(Suppl 1):S143–S158.CrossRefPubMed
45.
Rossi GP, Sacchetto A, Chiesura-Corona M, et al.: Identification of the etiology of primary aldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab 2001, 86:1083–1090.CrossRefPubMed
46.
Rossi GP, Ganzaroli C, Miotto D, et al.: Dynamic testing with high-dose adrenocorticotrophic hormone does not improve lateralization of aldosterone oversecretion in primary aldosteronism patients. J Hypertens 2006, 24:371–379.CrossRefPubMed
47.
Rossi GP, Pitter G, Miotto D: To stimulate or not to stimulate: is adrenocorticotrophic hormone testing necessary, or not? Round 2. J Hypertens 2007, 25:1518–1520.CrossRef
48.
Seccia TM, Miotto D, De Toni R, et al.: Adrenocorticotropic hormone stimulation during adrenal vein sampling for identifying surgically curable subtypes of primary aldosteronism: comparison of 3 different protocols. Hypertension 2009, 53:761–766.CrossRefPubMed
49.
• Miotto D, De Toni R, Pitter G, et al.: Impact of accessory hepatic veins on adrenal vein sampling for identification of surgically curable primary aldosteronism. Hypertension 2009, 54:885–889. This study described the impact of the presence of accessory hepatic veins on the right side on the results of AVS and highlighted the importance of superselective catheterization when such variants are identified.CrossRefPubMed
50.
Toniato A, Bernante P, Rossi GP, et al.: Laparoscopic versus open adrenalectomy: outcome in 35 consecutive patients. Int J Surg Investig 2000, 1:503–507.PubMed
Metadata
Title
Prevalence and Diagnosis of Primary Aldosteronism
Author
Gian Paolo Rossi
Publication date
01-10-2010
Publisher
Current Science Inc.
Published in
Current Hypertension Reports / Issue 5/2010
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-010-0134-2

Other articles of this Issue 5/2010

Current Hypertension Reports 5/2010 Go to the issue

Literature Alert

Prorenin: Where Does It Stand?

ReviewPaper

Does Blockade of the Renin-Angiotensin-Aldosterone System Slow Progression of All Forms of Kidney Disease?

ReviewPaper

Masked Hypertension: Evidence of the Need to Treat

ReviewPaper

Is the Presence of Microalbuminuria a Relevant Marker of Kidney Disease?

ReviewPaper

Chronic Kidney Disease and Albuminuria in Arterial Hypertension

Invited Commentary

The Diagnosis and Management of Syncope
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits